Esculin and esculetin protect against bone loss in osteoporosis by rebalancing osteoblast and osteoclast functions
- 1Department of Orthopedic Trauma, Nanyang Central Hospital
- 2Department of Gastroenterology and General Surgery, Nanyang Central Hospital
Abstract
Background: Osteoporosis is characterized by uncoupled bone remodeling where resorption outpaces formation. This study investigated the roles of two natural coumarins, Esculin (ECL) and Esculetin (ECLT), in bone metabolism.
Methods: We evaluated the bidirectional effects of ECL and ECLT on primary osteoblasts and RAW264.7-derived osteoclasts in vitro . In vivo , the translational protective efficacy of the compounds was assessed using ovariectomized (OVX) and sciatic nerve transection (DEN) mouse models, representing postmenopausal and disuse osteoporosis, respectively. Evaluations included serum biochemical analysis, histological staining, micro-computed tomography (Micro-CT), and three-point bending biomechanical tests.
Results: In vitro assays identified optimal pharmacological concentrations of 50 μM for ECL and 10 μM for ECLT, with both compounds dose-dependently promoting osteoblast proliferation and mineralization while simultaneously inducing osteoclast apoptosis and downregulating key resorptive genes. Co-administration of ECL and ECLT demonstrated enhanced efficacy, greater than either monotherapy in several key readouts. In both OVX and DEN in vivo models, the combinatorial regimen markedly ameliorated systemic inflammation and oxidative stress, and successfully rebalanced circulating bone turnover markers. Furthermore, the dual therapy robustly prevented the deterioration of three-dimensional trabecular and cortical bone microarchitecture and substantially improved the functional biomechanical strength of the femurs.
Conclusion: The concurrent application of ECL and ECLT protects against bone loss by concurrently promoting osteoblast function and suppressing osteoclast formation, representing a promising bidirectional strategy for osteoporosis management.
Related
- ARG2 drives osteoblast senescence by repressing mitophagy via the IκB-NF-κB-TXN2 signaling axis: implications for age-associated osteoporosis.
- Distinct osteoclast transcriptional states and heterotypic fusion arising from circulating pre-dendritic cells and monocytes
- 1α,25-(OH)2-D3 promotes osteoclast-precursor autophagy and osteoclast differentiation by promoting BECN1 transcription
- Transcription factor Fra-1 reprograms androgen receptor chromatin binding and super-enhancers in osteoblast differentiation
- In Silico and Experimental Evidence for Theasaponin E2 as a Modulator of the AKT1/GSK-3β Signaling Axis in Osteoclast Differentiation
BibTeX
@article{tong2026esculin,
title = {{Esculin and esculetin protect against bone loss in osteoporosis by rebalancing osteoblast and osteoclast functions}},
author = {Lei Tong and Weizhen Lv and Huaqing Liu},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1961311},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1961311/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Esculin and esculetin protect against bone loss in osteoporosis by rebalancing osteoblast and osteoclast functions
AU - Lei Tong
AU - Weizhen Lv
AU - Huaqing Liu
PY - 2026
DA - 2026/10/26
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1961311
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1961311/full
AB - Background: Osteoporosis is characterized by uncoupled bone remodeling where resorption outpaces formation. This study investigated the roles of two natural coumarins, Esculin (ECL) and Esculetin (ECLT), in bone metabolism. Methods: We evaluated the bidirectional effects of ECL and ECLT on primary osteoblasts and RAW264.7-derived osteoclasts in vitro . In vivo , the translational protective efficacy of the compounds was assessed using ovariectomized (OVX) and sciatic nerve transection (DEN) mouse models, representing postmenopausal and disuse osteoporosis, respectively. Evaluations included serum biochemical analysis, histological staining, micro-computed tomography (Micro-CT), and three-point bending biomechanical tests. Results: In vitro assays identified optimal pharmacological concentrations of 50 μM for ECL and 10 μM for ECLT, with both compounds dose-dependently promoting osteoblast proliferation and mineralization while simultaneously inducing osteoclast apoptosis and downregulating key resorptive genes. Co-administration of ECL and ECLT demonstrated enhanced efficacy, greater than either monotherapy in several key readouts. In both OVX and DEN in vivo models, the combinatorial regimen markedly ameliorated systemic inflammation and oxidative stress, and successfully rebalanced circulating bone turnover markers. Furthermore, the dual therapy robustly prevented the deterioration of three-dimensional trabecular and cortical bone microarchitecture and substantially improved the functional biomechanical strength of the femurs. Conclusion: The concurrent application of ECL and ECLT protects against bone loss by concurrently promoting osteoblast function and suppressing osteoclast formation, representing a promising bidirectional strategy for osteoporosis management.
SN - 1663-9812
ER -